



## Altimune to Announce Third Quarter 2019 Financial Results on November 14

November 6, 2019

GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and nine months ended September 30, 2019 before the market opens and host a conference call on Thursday, November 14, 2019.

### Conference Call Details

Date: Thursday, November 14  
Time: 8:30 am Eastern Time  
Domestic: 855-327-6837  
International: 631-891-4304  
Conference ID: 10008064  
Webcast: <http://public.viavid.com/index.php?id=136942>

### About Altimune

Altimune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™). For more information on Altimune, please visit [www.altimmune.com](http://www.altimmune.com).

### Contacts:

Will Brown  
Chief Financial Officer  
Phone: 240-654-1450  
[wbrown@altimmune.com](mailto:wbrown@altimmune.com)

Ashley R. Robinson  
LifeSci Advisors, LLC  
617-775-5956  
[arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)



Source: Altimune, Inc.